Anti-BCL2

B-cell lymphoma/leukaemia-2 (Bcl-2) is an inhibitor of apoptosis, and its expression is generally abundant in cells which dividing and differentiating. In lymphatic tissue, Bcl-2 is highly expressed in T-cells, maturating B cells as well as mature B-cells. However, expression level in germinal center B-cells is downregulated. Overexpression of the Bcl-2 is common in leukemia and various carcinomas and sarcomas. Overexpression is common especially in non-Hodgkins lymphoma. Bcl-2 is helpful to classification of the follicular lymphoma or other lymphomas Control: Appendix, tonsil. Protein function: Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785). [The UniProt Consortium]